ClinicalTrials.govpublic full text
A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy
unresectable or advanced clear cell renal cell carcinoma that has progressed after previous immunotherapy, js004, toripalimab, ccrcc, immunotherapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 876074
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.